Professor Joshua Sarnoff was quoted extensively in a recent BNA BioTech Watch article on the remand of the Myriad gene patent regarding the application of the Supreme Court’s unanimous decision in a case that found a medical treatment method not be to patent eligible subject matter, High Court's Mayo Standards Applicable To Myriad Remand Despite Case Differences, and was also quoted in a BNA Patent, Trademark & Copyright Journal article in regard to medical treatment method case, High Court's Unanimous Mayo Decision Provokes Mixed Reactions From Stakeholders.
Comments